<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865355</url>
  </required_header>
  <id_info>
    <org_study_id>MetGlio/19</org_study_id>
    <nct_id>NCT03865355</nct_id>
  </id_info>
  <brief_title>Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients</brief_title>
  <official_title>Unique Blood and CSF Metabolic Profile Association With Gliomas in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novosibirsk State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FSBI &quot;Federal Neurosurgical Center&quot; Novosibirsk, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FSBI &quot;Novosibirsk Research Institute of Traumatology and Orthopedics named after Ya. L. Tsiviyan&quot;, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novosibirsk State University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, non-interventional and translational clinical study. The aim of this&#xD;
      study is to analyze blood and cerebrospinal fluid metabolomic profile in glioma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The analysis of metabolic profile in the plasma and CSF could become the new less invasive&#xD;
      approach in the establishing diagnosis as well as an important prognostic factor in patients&#xD;
      with glioma. The researches will assess the blood and CSF metabolic profile in patients with&#xD;
      different types of gliomas as well as in patient without ones. This can help to find new&#xD;
      biomarkers for low- and high-grade gliomas correlating with patient outcomes.&#xD;
&#xD;
      Blood and CSF samples will be collected from patients with suspected newly diagnosed&#xD;
      low-grade (I-II) or high-grade (III-IV) gliomas as well as from patients who have&#xD;
      hospitalized for reconstructive surgery after craniofacial trauma. All samples will be&#xD;
      collected before any surgical intervention and at various follow-up time points until&#xD;
      progression or death. The results of the study are planned to be translated into the hospital&#xD;
      setting as support to other diagnostics procedures and to the differential diagnosis between&#xD;
      glioma grades.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Anticipated">April 11, 2029</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic phenotype of glioma patients</measure>
    <time_frame>5 years</time_frame>
    <description>Plasma and CSF aminoacids, acylcarnitines, and other metabolites in glioma patients compared to conditionally healthy volunteers by high-performance liquid chromatography coupled with tandem mass spectrometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Time between date of diagnosis and date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Time between date of diagnosis and date of disease progression</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glioma</condition>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Cohort 1 / High grade Glioma</arm_group_label>
    <description>Cohort 1:&#xD;
Histologically confirmed high-grade glioma (grade III and grade IV (glioblastoma (GBM)))&#xD;
Planned treatment (surgery followed by radiation therapy (RT) alone or Chemotherapy alone or a combination of RT/Chemotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 / Low grade Glioma</arm_group_label>
    <description>Cohort 2:&#xD;
Histologically confirmed low-grade (grade I/II) glioma&#xD;
Planned treatment either expectant monitoring or surgery followed by RT alone or Chemotherapy alone or a combination of RT/Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 / Conditionally healthy volunteers</arm_group_label>
    <description>Cohort 3:&#xD;
No oncological disease was diagnosed&#xD;
Planned treatment (reconstructive surgery after craniofacial trauma)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non- interventional</intervention_name>
    <description>Translational, observational study</description>
    <arm_group_label>Cohort 1 / High grade Glioma</arm_group_label>
    <arm_group_label>Cohort 2 / Low grade Glioma</arm_group_label>
    <arm_group_label>Cohort 3 / Conditionally healthy volunteers</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, cerebrospinal fluid (CSF)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with suspected newly diagnosed glioma with planned surgical intervention will&#xD;
        be eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All patients with suspected newly diagnosed glioma (grade I, II, III or glioblastoma)&#xD;
             with planned surgical intervention (resection or biopsy).&#xD;
&#xD;
          2. Patient aged 18 years or older&#xD;
&#xD;
          3. Patients have to be able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior Radiotherapy to the central nervous system&#xD;
&#xD;
          2. Prior Chemotherapy within the last 5 years&#xD;
&#xD;
          3. Any prior central nervous system malignancy&#xD;
&#xD;
          4. Any surgery during last 6 month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olga Oleshko, MD</last_name>
    <phone>+7 (913) 484-67-59</phone>
    <email>o.oleshko@g.nsu.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novosibirsk State University</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirskaya Oblast'</state>
        <zip>630090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Oleshko, MD</last_name>
      <email>o.oleshko@g.nsu.ru</email>
    </contact>
    <investigator>
      <last_name>Andrey Pokrovsky, DSc in Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolomic profile</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

